Evidence map›Paper›PMID 38934618›Full record

ArticlemBio2024

Unsaturated fatty acid perturbation combats emerging triazole antifungal resistance in the human fungal pathogen

Cecilia Gutierrez-Perez, Charles Puerner, Jane T Jones, Sandeep Vellanki, Elisa M Vesely, Mark A Xatse, Andre F C Viera, Carissa P Olsen, Keren O Attiku, Steven Cardinale and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Insights intomSphere · 2026
    Article
  2. Article
  3. Pathogenesis and Triazole Resistance inInfection and drug resistance · 2026
    Review
  4. Review
  5. Review
  6. Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Cecilia Gutierrez-PerezMicrobiology and Immunology Department, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA.ORCID 0000-0002-9808-0701
Charles PuernerMicrobiology and Immunology Department, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA.ORCID 0000-0002-4402-0295
Jane T JonesMicrobiology and Immunology Department, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA.
Sandeep VellankiMicrobiology and Immunology Department, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA.
Elisa M VeselyMicrobiology and Immunology Department, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA.
Mark A XatseDepartment of Chemistry and Biochemistry, Worcester Polytechnic Institute, Worcester, Massachusetts, USA.
Andre F C VieraDepartment of Chemistry and Biochemistry, Worcester Polytechnic Institute, Worcester, Massachusetts, USA.
Carissa P OlsenDepartment of Chemistry and Biochemistry, Worcester Polytechnic Institute, Worcester, Massachusetts, USA.
Keren O AttikuMicrobiology and Immunology Department, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA.
Steven CardinaleMicrobiotix Inc., Worcester, Massachusetts, USA.
Steven M KwasnyMicrobiotix Inc., Worcester, Massachusetts, USA.
Narendran G-DayanandanMicrobiotix Inc., Worcester, Massachusetts, USA.
Timothy J OppermanMicrobiotix Inc., Worcester, Massachusetts, USA.ORCID 0000-0003-2579-0427
Robert A CramerMicrobiology and Immunology Department, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA.ORCID 0000-0001-5503-5006

Funding

Understanding the role of RNA-binding protein mutations in cancerP20GM113132 · NIGMS · DARTMOUTH COLLEGE · PI MIERKE, DALE F · 2016 to 2025
$25.9M
Translational Research CoreP30DK117469 · NIDDK · DARTMOUTH COLLEGE · PI DEBORAH A HOGAN · 2018 to 2026
$13.9M
Overcoming Emerging Aspergillus fumigatus Azole Resistance Via Protease InhibitionR33AI140878 · NIAID · DARTMOUTH COLLEGE · PI CRAMER, ROBERT ANDREW · 2021 to 2023
$1.3M
CLC NIH HHS 75N90019D00022NIAID NIH HHS R33 AI140878NIDDK NIH HHS P30 DK117469NIGMS NIH HHS P20 GM113132NIMHD NIH HHS L60 MD001952ORFDO NIH HHS 75N99019D00022
6 · The paper itself

Abstract

Contemporary antifungal therapies utilized to treat filamentous fungal infections are inhibited by intrinsic and emerging drug resistance. Consequently, there is an urgent need to develop novel antifungal compounds that are effective against drug-resistant filamentous fungi. Here, we utilized an

Indexed as

Antifungal AgentsAspergillus fumigatusDrug Resistance, FungalFatty Acids, UnsaturatedMicrobial Sensitivity TestsTriazolesAnimalsCryptococcus neoformansDisease Models, AnimalDrug SynergismHigh-Throughput Screening AssaysHumansInvasive Pulmonary AspergillosisMicePiperidinesRhizopusAntifungal AgentsFatty Acids, UnsaturatedPiperidinesTriazolesantifungal agentsantifungal resistanceAspergillus fumigatusfatty acidssterol regulatory element binding protein

Identifiers

PMID38934618
PMCPMC11253624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.